Christopher Ridgeway
Founder and CEO of Stone Clinical Laboratories, with a career spanning medical services, laboratory development, medical device solutions, and healthcare business leadership.
Building healthcare businesses around unmet service needs.
Ridgeway’s career has developed across sales leadership, medical services, surgical technologies, clinical laboratory development, and specialty healthcare solutions.
Christopher Ridgeway has built his professional career around healthcare services, medical technology, clinical laboratory development, and the ability to identify additional service needs in the medical market.
Ridgeway founded Stone Clinical Laboratories as an expansion of Stone Surgical, which was established in 2008. The expansion followed his recognition of market demand for a broader range of clinical and laboratory services.
His experience also includes Stone Biotechnologies and a General Manager position with a national pharmacogenetics laboratory.
Full BiographyHealthcare experience at a glance.
Founder & CEO
Stone Clinical Laboratories
Clinical Solutions
Medical services, laboratory services, medical devices, specialty testing, and related clinical solutions.
Sales to Leadership
Sales, sales management, Stone Biotechnologies, and national pharmacogenetics laboratory leadership.
University Studies
University of Mississippi and University of New Orleans in Innsbruck, Austria.
New Orleans & Florida
Professional and personal ties to New Orleans, Louisiana and Florida.
Stone Surgical
Established in 2008.
Two complementary healthcare platforms.
Stone Surgical and Stone Clinical Laboratories reflect Ridgeway’s focus on integrating medical technology, specialty services, and clinical capabilities.
Medical services & surgical technology
Stone Surgical is a medical services company that provides advanced techniques and technologies to examination and surgical rooms, including medical device implants in neuro, spine, and orthopedics.
Clinical & laboratory services
Founded as an expansion after Ridgeway identified demand for a broader clinical offering, including toxicology, early-stage cancer detection, pharmacogenetics, pathology, wellness, testing, and related services.